AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

Phase 3AJ201Positive

AI Analysis

Summary

AnnJi Pharmaceutical has advanced AJ201 (rosolutamide), an oral small molecule, into pivotal Phase 3 ROMA-KD trial for spinal and bulbar muscular atrophy (SBMA). AJ201 is the only known investigational therapy for SBMA in Phase 3 development worldwide.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.60

Phase 3SBMAKennedy's diseaseRare diseaseOral small molecule

Read the original article

Published by PR Newswire Biotech on October 5, 2026 4:30 AM

Read Original